Use in Pregnancy: Category D: Cisplatin has been shown to be mutagenic in bacterial cultures and produces chromosome aberrations in animal cells in tissue culture. In mice cisplatin is teratogenic and embryotoxic, and its use in pregnant women is not recommended. Women of childbearing potential should use adequate contraception and cisplatin should only be used if the potential benefits outweigh the risk of therapy. If the patient becomes pregnant whilst receiving the drug she should be advised of the hazard to the fetus.
Use in Lactation: It is not known whether cisplatin is excreted in breast milk. However, because of the potential risk to the newborn it is recommended that breastfeeding be discontinued during therapy with cisplatin in lactating women.